Casos clínicos de eficacia y seguridad del fentanilo intranasal con pectina en la Unidad de Cuidados Paliativos y Hospitalización a Domicilio

Abstract

Breakthrough cancer pain is highly prevalent in palliative care patients. Depending on the series and disease stage, the incidence of breakthrough pain ranges from 70% to 90% of patients. The incapacitating nature of this pain is easily witnessed in daily clinical practice, as well as its huge impact on the quality of life of patients and their families. Moreover, unless breakthrough cancer pain is identified and correctly treated, it leads to huge personal and healthcare costs. However, the development of new therapeutic tools, such as fentanyl pectin nasal spray has represented a huge advance in the treatment of breakthrough pain. Due to both its clinical efficacy and ease of use by patients and their families, this medication has substantially reduced associated healthcare costs and has increased quality of life in palliative care patients.